GlassScriptPhysician profile
Bruno J Casile
NPI 1275762080
$21,012.52
in general payments reported to CMS, 2019-2025
47 companies · $3,583 in 2025
The $3,583 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,868 · 2020: $2,726 · 2021: $3,474 · 2022: $3,343 · 2023: $3,021 · 2024: $2,997 · 2025: $3,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,576 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,576.30 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,140.58 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $2,927.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,686.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,626.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,622.10 | 2019-2025 | |
| Amarin Pharma, INC. | $1,251.61 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,001.62 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Amgen INC. | $725.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $720.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $689.44 | 2019-2023 | Trintellix |
| Allergan, INC. | $547.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $528.82 | 2019-2025 | |
| Abbott Laboratories | $415.79 | 2022-2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $412.91 | 2019-2025 | Contrave, Onzetra Xsail, Nexletol |
| Exact Sciences Corporation | $380.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruno Casile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.